Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Type 2 diabetes medications

Journal articles and book chapters

07-30-2018 | Medications | Article

Choice of treatment regimen as add-on to insulin in Japanese patients with type 2 diabetes mellitus: Physicians’ perspective in a real-world setting, insight from a web survey

Imai K, Murayama H, Hirose T. Diabetes Ther 2018. doi: 10.1007/s13300-018-0476-3

07-28-2018 | Medications | Article

Changing use of antidiabetic drugs in the UK: Trends in prescribing 2000–2017

Wilkinson S et al. BMJ Open 2018; 8: e022768. doi: 10.1136/bmjopen-2018-022768

07-28-2018 | Dulaglutide | Article

Durability of glucose-lowering effect of the first administration of dulaglutide: A retrospective, single-center, single-arm study

Matsushita M et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0474-5

07-23-2018 | SGLT2 inhibitors | Review | Article

SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice

Wilding J et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0471-8

07-19-2018 | Semaglutide | Article

A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin

Lingvay I et al. Diabetes Care 2018: dc172381. doi: 10.2337/dc17-2381

07-17-2018 | Heart failure | Article

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Dawwas GK, Smith SM, Park H. Cardiovasc Diabetol 2018; 17: 102. doi: 10.1186/s12933-018-0746-4

07-17-2018 | Obesity | Review | Article

Weight management in patients with type 2 diabetes: A multidisciplinary real-world approach

Hamdy O, Ashrafzadeh S, Mottalib A. Curr Diab Rep 2018; 18: 66. doi: 10.1007/s11892-018-1030-4

07-16-2018 | Ipragliflozin | Article

Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): A 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study

Ishihara H et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0359-x

07-14-2018 | Metformin | Review | Article

Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? An alternative approach

Harrington JL et al. Curr Diab Rep 2018; 18: 64. doi: 10.1007/s11892-018-1035-z

07-03-2018 | Insulin glargine | Article

Switching from pre-mixed insulin to regimens with insulin glargine in type 2 diabetes: A prospective, observational study of data from Adriatic countries

Kelishadi R et al. Diabetol Metab Syndr 2018; 10: 52. doi: 10.1186/s13098-018-0352-3

07-03-2018 | Hypoglycemia | Article

Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes

Lipska KJ et al. JAMA 2018; 320: 53–62. doi: 10.1001/jama.2018.7993

06-30-2018 | Insulin NPH | Article

Glycemic control in hospitalized patients with diabetes receiving corticosteroids using a neutral protamine Hagedorn insulin protocol: A randomized clinical trial

Khowaja A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0468-3

06-30-2018 | Metformin | Review | Article

Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy

van Stee MF, de Graaf AA, Groen AK. Cardiovasc Diabetol 2018; 17: 94. doi: 10.1186/s12933-018-0738-4

06-27-2018 | Metformin | Article

Metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan

Matsuura N et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0361-3

06-27-2018 | Hyperglycemia | Article

Contribution of BHG and PPHG to overall hyperglycemia in T2DM patients treated with LM25 and LM50: Post hoc analysis of a randomized crossover trial

Li W et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0462-9

06-25-2018 | Cardiovascular disorders | Review | Article

Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment

Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5

06-25-2018 | Type 2 diabetes | Article

Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. Observations using the oral glucose tolerance test

The RISE Consortium. Diabetes Care 2018. doi: 10.2337/dc18-0243

06-25-2018 | Type 2 diabetes | Article

Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. Observations using the hyperglycemic clamp

The RISE Consortium. Diabetes Care 2018. doi: 10.2337/dc18-0244

06-25-2018 | Type 2 diabetes | Article

Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes

The RISE Consortium. Diabetes Care 2018. doi: 10.2337/dc18-0787

06-23-2018 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

Next Previous